Phase II study of the effect of the topical corticosteroid fluocinonide in patients on endocrine therapy for breast cancer or breast cancer prevention with symptoms of vaginal dryness and dyspareunia.

Authors

Evthokia A. Hobbs

Oregon Health & Science University, Portland, OR

Evthokia A. Hobbs , Kristine Lethert , Deirdre J. Nauman , Jenna Bucher , Emile Latour , Motomi Mori , Stephen Y. Chui , Kathleen A. Kemmer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Ultra-low doses of TX-004HR to improve symptoms of vulvar and vaginal atrophy (VVA) while maintaining serum levels of estradiol within the normal postmenopausal range.

First Author: Shari Beth Goldfarb

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials.

First Author: Claudia Omarini

insert_chart_outlined

Poster

2018 Palliative and Supportive Care in Oncology Symposium

bookmark_border

Fractional CO2 laser therapy for genitourinary syndrome of menopause (GSM) in survivors of breast cancer (BC).

First Author: Allison M Quick

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (≤ 25).

First Author: Maysa M. Abu-Khalaf